1. Regulatory framework for advanced therapy medicinal products in Europe and United States;Iglesias-Lopez;Front Pharmacol,2003
2. US Food and Drug Administration. Fast track, breakthrough therapy, accelerated approval, priority review.https://www.fda.gov/patients/learn-about-drug-and-device-approvals/fast-track-breakthrough-therapy-accelerated-approval-priority-review>; 2018 [accessed 26.12.2023]
3. European Medicines Agency (EMA). Guidance for applicants seeking access to PRIME scheme. ; 2023a [accessed 26.12.2023]
4. European Medicines Agency (EMA). Guideline on Scientific Requirements for the Environmental Risk Assessment of Gene Therapy Medicinal Products (EMEA/CHMP/GTWP/125491/2006). ; 2008 [accessed 26.12.2023]
5. Environmental health and biosafety risk assessment guidance for commercial-scale cell and gene therapy manufacturing;DiGiandomenico;Appl Biosaf,2020